Josh Poorbaugh

The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

Robert J. Benschop, Jay Tuttle, Lin Zhang et al. · Science Translational Medicine · 2022 · 36 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

Peter Chen, Gourab Datta, Ying Grace Li et al. · Clinical Pharmacology & Therapeutics · 2021 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX® and Quanterix SiMoA methodologies

Josh Poorbaugh, Tanushree Samanta, Stuart W. Bright et al. · Journal of Immunological Methods · 2018 · 29 citations

Life Sciences, Immunology, Clinical Immunology +14

Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of <scp>IL‐17A</scp> ( <scp>LY3509754</scp> ): A Phase I Randomized Placebo‐Controlled Study

Amita Datta‐Mannan, Arie Regev, David E. Coutant et al. · Clinical Pharmacology & Therapeutics · 2024 · 27 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

Lin Zhang, Josh Poorbaugh, Michael Dougan et al. · Frontiers in Immunology · 2021 · 24 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17